These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
375 related items for PubMed ID: 11739384
1. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. J Biol Chem; 2002 Feb 15; 277(7):4656-62. PubMed ID: 11739384 [Abstract] [Full Text] [Related]
2. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Biochem Biophys Res Commun; 2002 Jun 14; 294(3):700-9. PubMed ID: 12056827 [Abstract] [Full Text] [Related]
3. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ. Mol Cell Biol; 2002 Mar 14; 22(6):1947-60. PubMed ID: 11865071 [Abstract] [Full Text] [Related]
4. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD. Proc Natl Acad Sci U S A; 1997 Mar 18; 94(6):2156-61. PubMed ID: 9122164 [Abstract] [Full Text] [Related]
5. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831 [Abstract] [Full Text] [Related]
6. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. Genes Dev; 1999 Jul 15; 13(14):1822-33. PubMed ID: 10421634 [Abstract] [Full Text] [Related]
8. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. Miller F, Kentsis A, Osman R, Pan ZQ. J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064 [Abstract] [Full Text] [Related]
9. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product. Pereira T, Zheng X, Ruas JL, Tanimoto K, Poellinger L. J Biol Chem; 2003 Feb 28; 278(9):6816-23. PubMed ID: 12468553 [Abstract] [Full Text] [Related]
10. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. Li Z, Wang D, Messing EM, Wu G. EMBO Rep; 2005 Apr 28; 6(4):373-8. PubMed ID: 15776016 [Abstract] [Full Text] [Related]
15. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Tanimoto K, Makino Y, Pereira T, Poellinger L. EMBO J; 2000 Aug 15; 19(16):4298-309. PubMed ID: 10944113 [Abstract] [Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin T. J Biol Chem; 2001 Nov 23; 276(47):43611-7. PubMed ID: 11574546 [Abstract] [Full Text] [Related]
19. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. J Biol Chem; 2001 May 04; 276(18):15306-15. PubMed ID: 11278694 [Abstract] [Full Text] [Related]
20. Comparative sequence analysis of the VHL tumor suppressor gene. Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER. Genomics; 2000 May 01; 65(3):253-65. PubMed ID: 10857749 [Abstract] [Full Text] [Related] Page: [Next] [New Search]